Cyber PMS Adopted for One-Stop Post-Marketing Surveillance Solution within IQVIA Japan Group
New Medical Real World Data Research Institute (PRiME-R) and IQVIA Japan Group have partnered to launch a one-stop solution for post-marketing surveillance (PMS). This collaboration combines PRiME-R's Cyber PMS with IQVIA's expertise to reduce the burden on medical institutions and improve data quality.
📋 Article Processing Timeline
- 📰 Published: May 13, 2026 at 22:00
- 🔍 Collected: May 13, 2026 at 13:31
- 🤖 AI Analyzed: May 13, 2026 at 14:07 (35 min after Collected)
New Medical Real World Data Research Institute, Inc. (Headquarters: Kyoto City, President and CEO: Koji Korekawa, hereinafter 'PRiME-R'), following its collaboration*1 with IQVIA Services Japan G.K. (Location: Minato-ku, Tokyo, President: Fumihiko Ugajin, hereinafter IQVIA) of the IQVIA Japan Group in clinical research, has commenced providing integrated support services for post-marketing surveillance (hereinafter 'PMS') as well.
*1 Cyber Oncology® Adopted for One-Stop Clinical Research Solution within IQVIA Japan Group https://prime-r.inc/newsrelease/734/
1. Background of the Initiative
In recent years, as the need for PMS utilizing Real World Data (RWD) has increased, both medical institutions and pharmaceutical companies are seeking efficient and high-quality PMS implementation.
PRiME-R began providing oncology PMS support services based on Cyber Oncology® as Cyber PMS in June 2025, as a service that reduces the data entry burden on medical institutions and enables high-quality data collection.
Through this collaboration, by combining IQVIA's long-standing PMS experience and know-how with PRiME-R's RWD platform, a system will be established to consistently support PMS from planning to implementation and reporting.
*Regarding the start of PMS support service provision https://prime-r.inc/newsrelease/893/
2. Overview and Features of this Solution
■ Reducing burden on medical sites and improving data quality
Cyber PMS can be launched and linked from electronic medical record terminals, and is equipped with functions such as audit trails, electronic signatures, and account management in compliance with ER/ES guidelines*2. Compared to EDC, it allows for more efficient PMS implementation, thereby reducing the burden on medical institutions while achieving high-quality data collection.
*2 PMS is conducted based on the "Ordinance on Standards for Conducting Post-Marketing Surveys and Tests of Pharmaceuticals" (Ministry of Health, Labour and Welfare Ordinance No. 171 of December 20, 2004) (GPSP Ordinance), and when using systems, it must comply with the "Guidelines on the Use of Electronic Records and Electronic Signatures in Applications for Approval or Permission of Pharmaceuticals, etc." (Yakushokuhatsu No. 0401022 of April 1, 2005) (ER/ES Guidelines).
■ Provision of one-stop PMS support services
By integrating PRiME-R's developed Cyber PMS with IQVIA's long-standing PMS experience and know-how, the solution supports the product lifecycle from survey planning to re-examination applications.
■ Establishment of an implementation foundation as an IQVIA Qualified Vendor, anticipating practical operations
PRiME-R has been confirmed as an IQVIA Qualified Vendor regarding its quality management system and the development of related SOPs. This ensures that pharmaceutical companies have a pre-established system in place for post-introduction operations, contributing to the smooth execution of contract and setup processes.
3. Future Developments
This collaboration is not merely about system provision; it aims to comprehensively resolve various issues arising in the implementation and operation of PMS, including reducing the burden on medical institutions.
PRiME-R will continue to promote the utilization of RWD through clinical research support using Cyber Oncology® and PMS implementation support services using Cyber PMS, striving for the development of next-generation medicine. We kindly ask for your continued support.
*1 Cyber Oncology® Adopted for One-Stop Clinical Research Solution within IQVIA Japan Group https://prime-r.inc/newsrelease/734/
1. Background of the Initiative
In recent years, as the need for PMS utilizing Real World Data (RWD) has increased, both medical institutions and pharmaceutical companies are seeking efficient and high-quality PMS implementation.
PRiME-R began providing oncology PMS support services based on Cyber Oncology® as Cyber PMS in June 2025, as a service that reduces the data entry burden on medical institutions and enables high-quality data collection.
Through this collaboration, by combining IQVIA's long-standing PMS experience and know-how with PRiME-R's RWD platform, a system will be established to consistently support PMS from planning to implementation and reporting.
*Regarding the start of PMS support service provision https://prime-r.inc/newsrelease/893/
2. Overview and Features of this Solution
■ Reducing burden on medical sites and improving data quality
Cyber PMS can be launched and linked from electronic medical record terminals, and is equipped with functions such as audit trails, electronic signatures, and account management in compliance with ER/ES guidelines*2. Compared to EDC, it allows for more efficient PMS implementation, thereby reducing the burden on medical institutions while achieving high-quality data collection.
*2 PMS is conducted based on the "Ordinance on Standards for Conducting Post-Marketing Surveys and Tests of Pharmaceuticals" (Ministry of Health, Labour and Welfare Ordinance No. 171 of December 20, 2004) (GPSP Ordinance), and when using systems, it must comply with the "Guidelines on the Use of Electronic Records and Electronic Signatures in Applications for Approval or Permission of Pharmaceuticals, etc." (Yakushokuhatsu No. 0401022 of April 1, 2005) (ER/ES Guidelines).
■ Provision of one-stop PMS support services
By integrating PRiME-R's developed Cyber PMS with IQVIA's long-standing PMS experience and know-how, the solution supports the product lifecycle from survey planning to re-examination applications.
■ Establishment of an implementation foundation as an IQVIA Qualified Vendor, anticipating practical operations
PRiME-R has been confirmed as an IQVIA Qualified Vendor regarding its quality management system and the development of related SOPs. This ensures that pharmaceutical companies have a pre-established system in place for post-introduction operations, contributing to the smooth execution of contract and setup processes.
3. Future Developments
This collaboration is not merely about system provision; it aims to comprehensively resolve various issues arising in the implementation and operation of PMS, including reducing the burden on medical institutions.
PRiME-R will continue to promote the utilization of RWD through clinical research support using Cyber Oncology® and PMS implementation support services using Cyber PMS, striving for the development of next-generation medicine. We kindly ask for your continued support.